Table 2.

Baseline demographics and clinical characteristics in DIALOGUEs 1, 2, and 4

Patient CharacteristicsDIALOGUE 1DIALOGUE 2DIALOGUE 4
Molidustata (n=101)Placebo (n=20)Molidustata (n=92)Darbepoetin (n=32)Molidustata (n=157)Epoetin (n=42)
Mean age, yr (SD)69 (12)67 (16)68 (11)69 (9)59 (13)59 (9)
Women, n (%)45 (45)11 (55)47 (51)14 (44)66 (42)13 (31)
Race, n (%)
 White63 (62)15 (75)69 (75)25 (78)84 (54)18 (43)
 Asian38 (38)5 (25)22 (24)6 (19)29 (18)7 (17)
 Black001 (1)1 (3)40 (25)17 (40)
 Other00004 (3)0
Mean CKD duration, yr (SD)4.5 (4.5)3.5 (2.7)6.7 (6)5.8 (5)6 (6.2)6 (4.3)
Mean dialysis therapy duration, yr (SD)5 (5.2)5 (4.0)
CKD etiology, n (%)b
 Diabetes45 (45)9 (45)31 (34)10 (31)86 (55)24 (57)
 Hypertension45 (45)6 (30)31 (34)13 (41)48 (31)18 (43)
Mean eGFR, ml/min per 1.73 m2 (SD)c23 (12)23 (12)20 (11)22 (12)
Mean Hb level, g/dl (SD)9.5 (0.7)9.5 (0.6)10.8 (0.7)10.9 (0.7)10.5 (0.6)10.6 (0.5)
Mean prior ESA dose (µg/kg per wk) before randomization (SD)0.2 (0.2)0.3 (0.2)114 (98)103 (89)
Mean C-reactive protein, mg/L (SD)7.2 (16.4)4.3 (5.1)7.4 (14.9)6.5 (11.2)0.8 (1.4)0.7 (1.1)
  • DIALOGUE, DaIly orAL treatment increasing endOGenoUs Erythropoietin; –, not applicable; Hb, hemoglobin; ESA, erythropoiesis-stimulating agents.

  • a For DIALOGUE 2 and DIALOGUE 4, doses represent starting doses only.

  • b Patients could have more than one etiology of CKD and the two most common etiologies are shown here. Other etiologies included autoimmune disease, cardiac diseases, GN, infection, and polycystic kidney disease.

  • c eGFR was calculated using the Modification of Diet in Renal Disease formula.